PRX 105

Drug Profile

PRX 105

Alternative Names: PRX-105

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Boyce Thompson Institute for Plant Research
  • Developer Protalix BioTherapeutics; Yissum Research Development Company
  • Class Enzymes
  • Mechanism of Action Cholinesterase stimulants; Scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Parkinson's disease; Poisoning

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Poisoning(In volunteers) in Israel (IV, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Poisoning(In volunteers) in USA (IV, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top